Key TakeawaysThe weight-loss drug tirzepatide reduced both body fat and tumor growth in obese mice with breast cancer. Tumor ...

In postmenopausal women with overweight or obesity receiving tirzepatide, use of menopausal hormone therapy (MHT) is ...

Eli Lilly says GIP/GLP-1 agonist tirzepatide can reduce the risk of diabetes in overweight, obese people with prediabetes.

Eli Lilly's dual GLP-1/GIP agonist tirzepatide has been shown to reduce the risk of worsening disease in people with heart failure and obesity in a phase 3 trial, the first to show a benefit on ...

Myeloma Trial Results Spark Talk of 'Potential Cure' — One-third of patients alive and progression-free 5 or more years after a single infusion ...